Search
Filter Results
- Resource Type
- Article1
- Book1
- Book Digital1
- Article Type
- Research Support, U.S. Gov't, P.H.S.1
- Result From
- Lane Catalog1
- PubMed1
-
Year
- Journal Title
- J Exp Med1
Search Results
Sort by
- BookOrit Kaidar-Person, Ronald Chen, editors.Summary: This handbook summarizes the data and techniques for hypofractionation and stereotactic radiation in a clinically-accessible way. Hypofractionated radiation therapy, which consists of larger-dose radiation treatments that are given over a shorter time period compared to conventional radiation fraction sizes, is used to treat a variety of cancers, including prostate, breast, lung, and colorectal. Conventional radiation therapy and hypofractionated radiation therapy have different effectiveness rates for cancer treatment and have different impacts on normal tissues in terms of causing toxicity. There is a significant and growing body of literature on the use of different dosing regimens to treat a variety of cancers and radiation oncologists need to keep up with the various dosing schedules, the effect of each regimen on cancer control in different cancers, and how the different schedules affect each organ in terms of toxicity. The book thus provides concise information ranging from commonly-used dose-fractionation schemes for hypofractionated and stereotactic body radiotherapy to simulation and treatment specifications to published safety and efficacy data. Chapters additionally examine the biological rationales for the efficacy of hypofractionated radiation; present clinical studies that demonstrate the efficacy and safety of hypofractionated radiation treatment in a variety of cancers; and describe the advances in technology that have allowed hypofractionated radiation to be safely given. This is an ideal guide for radiation oncology clinicians and trainees.
- ArticleMcKenzie IF, Henning MM.J Exp Med. 1978 Feb 01;147(2):611-6.Nude (athymic) or anti-lymphocyte serum-treated mice have absent delayed graft rejection due to impaired T-cell responses. Nonetheless, these mice can reject skin grafts, acutely, when treated with anti-H-2 antibody and additional complement. Resolution of the components in the H-2 antisera, by either absorption or by selective production of antisera of restricted specificity has demonstrated that anti-H-2K or H-2D antiser are graft destructive, and as shown elsewhere, are nonenhancing. By contrast, anti-Ia sera are not capable of causing allograft destruction even when used in extremely high doses and were previously noted to be enhancing. The mechanism of such differential effects is not apparent, but the findings are clearly of importance to transplantation in man, where sera reacting specifically with B cells may also be enhancing and nondestructive.